Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1)

Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma

(2014) Dino Luethi et al.   BIOMEDICAL CHROMATOGRAPHY

P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice

(2014) S. C. Tang et al.   CLINICAL CANCER RESEARCH

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

(2014) F. Lin et al.   CLINICAL CANCER RESEARCH

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study

(2013) Jordi Bruix et al.   EUROPEAN JOURNAL OF CANCER

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

(2013) Seng Chuan Tang et al.   INTERNATIONAL JOURNAL OF CANCER

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387

(2013) S. Durmus et al.   PHARMACOLOGICAL RESEARCH

Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones

(2012) Anita C. A. Dankers et al.   CELL AND TISSUE RESEARCH

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up

(2012) Sagar Agarwal et al.   CURRENT PHARMACEUTICAL DESIGN

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Oral Availability and Brain Penetration of the B-RAFV600E Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar

(2012) Selvi Durmus et al.   MOLECULAR PHARMACEUTICS

Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics

(2011) B. Poller et al.   DRUG METABOLISM AND DISPOSITION

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors

(2011) Yasuo Uchida et al.   JOURNAL OF NEUROCHEMISTRY

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice

(2010) H Sallinen et al.   CANCER GENE THERAPY

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone

(2010) H. Kodaira et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

(2010) S. Agarwal et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation

(2010) J. S. Lagas et al.   MOLECULAR CANCER THERAPEUTICS

Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity

(2009) R. A.B. van Waterschoot et al.   CANCER RESEARCH

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters

(2009) S. Hu et al.   CLINICAL CANCER RESEARCH

P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib

(2009) Y. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic Therapy

(2009) J. H. Tsai et al.   MOLECULAR CANCER RESEARCH

Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function

(2008) M. J. Zamek-Gliszczynski et al.   DRUG METABOLISM AND DISPOSITION

Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria

(2008) Junichi Kamiie et al.   PHARMACEUTICAL RESEARCH